Structure/Function Claims Readiness: Staying on the Right Side of the DSHEA §6 Line
Structure/function claims are the marketing oxygen of the dietary supplement category.
In Short
- DSHEA §6 (codified at FDCA §403(r)(6)) allows a dietary supplement label to describe how a nutrient or dietary ingredient affects the structure or function of the…
- FDA's 2002 final rule on structure/function claims ("Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or…
- FDA reviews labels.
A claim that describes the role of a nutrient or dietary ingredient in maintaining normal structure or function ("calcium supports bone health") is allowed under DSHEA §6 with a 30-day FDA notification, a mandatory disclaimer, and a substantiation file. A claim that states or implies the product diagnoses, treats, cures or prevents a disease ("lowers cholesterol") is a drug claim and is not allowed on a supplement label without drug approval. The line is enforced by both FDA (label, warning letters) and FTC (advertising, consent decrees). This guide maps where the line actually is and how V5 holds the substantiation behind it.
The DSHEA §6 envelope: what a structure/function claim can say
DSHEA §6 (codified at FDCA §403(r)(6)) allows a dietary supplement label to describe how a nutrient or dietary ingredient affects the structure or function of the human body, or characterise the documented mechanism by which it acts, or describe general well-being. The claim must be truthful and not misleading, the manufacturer must have substantiation, and the label must carry the mandatory disclaimer: "This statement has not been evaluated by the Food and Drug Administration.
More on the DSHEA §6 envelope: what a structure/function claim can say
This product is not intended to diagnose, treat, cure or prevent any disease." The 30-day post-market notification to FDA's Office of Dietary Supplement Programs is mandatory under 21 CFR 101.93.
The disease-claim cliff and FDA's working test
FDA's 2002 final rule on structure/function claims ("Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body") gives the working test for disease versus non-disease claims. A claim implies disease treatment if it (1) names a specific disease, (2) names a disease's characteristic signs or symptoms, (3) implies the product treats a disease class, (4) uses scientific or lay terminology recognised by the public as disease-related, (5) cites disease-treatment authorities, or (6) implies disease treatment through product name, ingredient name, vignette, or testimonial.
More on the disease-claim cliff and FDA's working test
Warning letters cluster on signs-and-symptoms language ("reduces joint pain", "clears congestion") and on testimonials that name a disease the product is not approved to treat.
The substantiation file: FTC's standard, not FDA's
FDA reviews labels. FTC reviews advertising, and FTC's substantiation standard is the one that actually defines what evidence a structure/function claim needs.
More on the substantiation file: FTC's standard, not FDA's
FTC's 1998 Dietary Supplements Advertising Guide and its 2022 Health Products Compliance Guidance set the standard at "competent and reliable scientific evidence" — typically randomised controlled trials in the proposed population at the proposed dose, with results supporting the specific claim language. A claim supported only by mechanism-of-action data, animal studies, or trials in unrelated populations is exposed to an FTC challenge that ends in a consent decree and disgorgement. Substantiation is held before the claim is made, not assembled after the challenge.
The 30-day FDA notification and the post-market window
21 CFR 101.93 requires the manufacturer to notify FDA within 30 days of first marketing a structure/function claim, giving the exact claim language, the product name, and the manufacturer's contact information. FDA does not approve the claim — it logs it.
More on the 30-day FDA notification and the post-market window
But the notification creates a public record FDA's post-market team can audit against the actual label, and a mismatch (label says one thing, notification says another) is itself a finding. The notification also starts FDA's clock for any disease-claim challenge, because the agency is now on notice of the marketed claim.
A 60-day claim portfolio readiness path
- Days 1–10
claim inventory — every marketed claim across every product, every channel (label, web, retailer detail page, ad).
- Days 11–25
disease-claim screen — every claim run through the six-factor FDA test, with disposition (keep, modify, remove).
- Days 26–40
substantiation gap analysis — every kept claim mapped to its competent-and-reliable evidence with FTC-class sufficiency.
- Days 41–50
21 CFR 101.93 notification reconciliation.
- Days 51–60
artwork and digital-content remediation with mandatory-disclaimer audit.
Questions
Do I need FDA approval for a structure/function claim?
No — FDA does not approve structure/function claims. The manufacturer is responsible for substantiation. A 30-day post-market notification under 21 CFR 101.93 is required, but it is notification, not approval.
Is the disclaimer really mandatory on every label?
Yes, on any label or labelling carrying a structure/function claim. The disclaimer text is specified at FDCA §403(r)(6) and must appear in connection with the claim. Missing disclaimer is one of the most common warning-letter findings.
Can a testimonial cross into a disease claim?
Yes — and frequently does. A testimonial that names a disease the product helped ("after taking this my arthritis improved") makes the product an unapproved drug regardless of the product label. FTC and FDA both treat testimonials as the brand's own claims for substantiation and label purposes.
What is FTC's substantiation standard?
"Competent and reliable scientific evidence" — defined in the 2022 Health Products Compliance Guidance as evidence that experts in the relevant field would accept as adequate to support the specific claim. For most structure/function claims FTC expects randomised controlled trials in the relevant population at the relevant dose.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
- The rules and who decides
- Specification to finished batch
- Test, review, investigate
- Labels, samples and recall
Plus Evidence map and four worksheets.
Get the supplement guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
Keep reading
Dietary Supplement cGMP Readiness: Handoffs and Audit Evidence- 21 CFR 111 Readiness: Identity, Master and Batch Records
NDI Notification under 21 CFR 190.6: Contents, the 75-Day Wait and Amendments
NSF 173 & USP <2750> Readiness: Third-Party Supplement Certification
Supplement Complaint and Adverse Event Reporting Readiness: U.S. Guide
Supplement Distribution, Holding and Returned Product Readiness Guide